2型糖尿病患者治疗前后部分骨和矿物质代谢指标的变化及意义  

Change of some bone metabolic markers of type 2 diabetic patients before and after treatment

作　　者：陈慧[1] 张宏刚[1] 倪安民[1] 陈雪红[1] 万晓辉[1] 

机构地区：[1]兰州医学院第二附属医院,甘肃兰州730030

出　　处：《中国老年学杂志》2004年第11期998-999,共2页Chinese Journal of Gerontology

摘　　要：目的　观察 2型糖尿病 (T2DM)患者血糖水平与钙尔奇D对T2DM患者骨和矿物质代谢的影响。方法　以饮食控制和口服降糖药物的T2DM患者为对象 ,根据血糖水平和治疗设立血糖正常组、钙尔奇D组和高血糖组。连续治疗 3个月 ,测定所有受试者治疗前后血清总钙、磷、碱性磷酸酶 (AKP)、骨钙素 (BGP)、Ⅰ型胶原羟基肽 (ICTP)和L2L4骨密度 (BMD)。结果　钙尔奇D治疗组血清BGP较治疗前明显上升 (P <0 0 5) ;两组患者的BMD在治疗后似呈上升趋势。结论　良好控制血糖是延缓或防止T2DM患者骨矿物质异常代谢或骨质疏松的关键 。Objective To evaluate the effects of nor ma l blood glucose (BG) level and Caltrate D on bone mineral metabolism in type 2 d iabetic patients. Methods According to the blood glucos e level and treatment, all type 2 diabetic patients with diet controlling and an tidiabetes drugs treatment were divided into normal blood glucose group, Caltrat e D group and high blood glucose group.The level of serum Ca, P, AKP, BGP, ICTP and BMD of L1 - L4 were measured in all patients before and 3 months after tre atment. Results After the treatment, the BGP level in s erum increased obviously and ICTP in serum has a decrease trend in Caltrate D gr oup, and BGP in serum increased slightly in normal blood glucose group (P<0. 01, P>05 and P<0.05, respectively). BMD tended upwards in cultrate D g roup and normal glucose group. Conclusions Better contr olling blood glucose is the key to delay and prevent bone mineral metabolism and osteoporosis in patients with type 2 diabetic mellituss, and uniting Caltrate D and VitD3 can turn effectively their above abnormalities.

关 键 词：2型糖尿病 骨矿代谢 钙尔奇D 疗效 

分 类 号：R587.1[医药卫生—内分泌]